1447-0756/asset/JOG_left.gif?v=1&s=5077c1b670807015301d074d6f555f0c7129ba8c)
1447-0756/asset/JOG_right.gif?v=1&s=4a3d984eea92b5fe8083ee1c0f5e1f037893c769)
Original Article
You have free access to this content
Increased incidence of brain metastases in BRCA1-related ovarian cancers
Article first published online: 13 AUG 2012
DOI: 10.1111/j.1447-0756.2012.01961.x
© 2012 The Authors. Journal of Obstetrics and Gynaecology Research © 2012 Japan Society of Obstetrics and Gynecology
Additional Information
How to Cite
Sekine, M., Yoshihara, K., Komata, D., Haino, K., Nishino, K. and Tanaka, K. (2013), Increased incidence of brain metastases in BRCA1-related ovarian cancers. Journal of Obstetrics and Gynaecology Research, 39: 292–296. doi: 10.1111/j.1447-0756.2012.01961.x
Publication History
- Issue published online: 7 JAN 2013
- Article first published online: 13 AUG 2012
- Received: January 13 2012.; Accepted: April 13 2012.
References
- 1, , , , . Brain metastases of epithelial ovarian carcinoma responding to cisplatin and gemcitabine combination chemotherapy: A case report and review of the literature. Gynecol Oncol 2004; 94: 267–276.
- 2, , et al. Cerebral metastases secondary to ovarian cancer: Still an unusual event. Gynecol Oncol 1993; 49: 37–40.
- 3, . Cerebral metastases in patients with ovarian cancer treated with chemotherapy. Gynecol Oncol 1989; 33: 296–300.
- 4, , , , , . Central nervous system metastases in patients with ovarian carcinoma. A report of 23 cases and a literature review. Ann Oncol 1995; 6: 571–574.
- 5, , et al. A strong candidate for the breast and ovarian-cancer susceptibility gene BRCA1. Science 1994; 266: 66–71.
- 6, , , , . Two BRCA1-positive epithelial ovarian tumors with metastases to the central nervous system: A case report. Gynecol Oncol 2001; 80: 399–402.
- 7, , et al. The Japanese Familial Ovarian Cancer Study Group. Mutational analysis of BRCA1 and BRCA2 and clinicopathologic analysis of ovarian cancer in 82 ovarian cancer families: Two common founder mutations of BRCA1 in Japanese population. Clin Cancer Res 2001; 7: 3144–3150.
- 8, , et al. Screening of BRCA1 mutation using immunohistochemical staining with C-terminal and N-terminal antibodies in familial ovarian cancers. Jpn J Cancer Res 2000; 91: 399–409.
- 9, , . Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 1995; 56: 265–271.
- 10, , , . The genetic attributable risk of breast and ovarian cancer. Cancer 1996; 77: 2318–2324.
- 11, , et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 2000; 283: 2260–2265.
- 12, , et al. Clinical features of ovarian cancer in Japanese women with germ-line mutations of BRCA1. Clin Cancer Res 1998; 4: 235–240.
- 13, . Brain metastases from epithelial ovarian cancer. Int J Gynecol Cancer 2005; 15: 824–829.
- 14, , , . Response of brain metastases from breast cancer to systemic chemotherapy. Cancer 1992; 69: 972–980.
- 15. BRCA1: Cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution. Nucleic Acids Res 2007; 34: 1416–1426.
- 16. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 2002; 108: 171–182.
- 17. Tumor formation in BRCA1 conditional mutant mice. Environ Mol Mutagen 2002; 39: 171–177.
- 18
- 19, , , . BRCA1 mutation and neuronal migration defect: Implications for chemoprevention. J Med Genet 2005; 42: 24–25.
- 20, , et al. Expression of metastasis-related nm23-H1 and nm23-H2 genes in ovarian carcinomas: Correlation with clinicopathology, EGFR, c-erbB-2, and c-erbB-3 genes, and sex steroid receptor expression. Cancer Res 1994; 54: 1825–1830.
- 21, , et al. Crosstalk between EGFR and TrkB enhances ovarian cancer cell migration and proliferation. Int J Oncol 2007; 29: 1003–1011.